Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/18/12/1969/560540/mdm372.pdf
Reference43 articles.
1. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene;Slamon;Science,1987
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989
3. The biology of erbB-2/neu/HER-2 and its role in cancer;Hynes;Biochim Biophys Acta,1994
4. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers—a review;Ravdin;Gene,1995
5. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Charles;J Clin Oncol,2002
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial;Cancer Pathogenesis and Therapy;2024-01
2. Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer;Breast Care;2014
3. Preparation, Characterization, and In Vitro Release of Vinorelbine Tartrate (VLBT)- Loaded Folate-conjugated Recombination Human Serum Albumin (rHSA) Nanoparticles with Different Degree of Cross-linking;Current Nanoscience;2012-11-01
4. Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs;Cancer du sein;2012
5. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer;Annals of Oncology;2011-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3